Schedule 13D ownership disclosure

Armata Pharmaceuticals, Inc.

Common Stock, $0.01 par value · CUSIP: 04216R102

Event date: 2026-01-23

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Innoviva, Inc.Reported CIK 0001080014

    Shares: 55,467,459.00 · Class: 83.1%

  • Innoviva Strategic Opportunities LLCReported CIK 0001842875

    Shares: 46,756,659.00 · Class: 70.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001140361-26-002376
Form type
SCHEDULE 13D/A
Filer
Armata Pharmaceuticals, Inc.
CIK
CIK 921114
Filed
Jan 26, 2026
Reporting period
Jan 23, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub